ERAS

Erasca, Inc. (ERAS) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Erasca, Inc. is a clinical-stage precision oncology company focused on discovering and developing therapies for RAS/MAPK pathway-driven cancers. The company operates as a single segment and has no approved products or product revenue. It is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Increase in Net Loss: Net loss increased by $152.5 million year-over-year, primarily driven by a one-time $150.0 million in-process research and development (IPR&D) expense. This expense resulted from the exercise of an option to expand the territory of a license agreement with Guangzhou Joyo Pharmatech Co., Ltd. to include mainland China, Hong Kong, and Macau.
• Capital Raise: In January 2026, the company completed an underwritten offering of 25,875,000 shares at $10.00 per share, generating net proceeds of $242.7 million. This significantly bolstered liquidity compared to the prior period.
• Operating Expenses: Excluding the IPR&D charge, core operating expenses (R&D and G&A) increased modestly. R&D rose to $27.3 million (from $26.0 million) due to increased personnel costs and clinical trial activities. G&A rose to $10.6 million (from $9.7 million) primarily due to personnel costs.
• Investing Activities: Net cash used in investing activities was $243.8 million, driven by the $150.0 million IPR&D payment and net purchases of marketable securities, partially offset by sales and maturities of securities.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes cash, cash equivalents, and marketable securities of $408.5 million are sufficient to fund operations into the second half of 2028.
• Clinical Progress:
  • ERAS-0015 (Pan-RAS molecular glue): Positive preliminary Phase 1 data announced in April 2026 showed robust monotherapy response rates in NSCLC and PDAC. The company selected 24 mg and 32 mg QD as recommended doses for expansion. Collaborations with Tango Therapeutics and Merck are underway.
  • ERAS-4001 (Pan-KRAS inhibitor): Phase 1 monotherapy data readout is anticipated in the second half of 2026.
  • Naporafenib: The company terminated its license agreement with Novartis for naporafenib in March 2026 to prioritize its RAS-targeting franchise. Patients in existing trials will continue treatment.
• Key Risk - Intellectual Property Litigation: On April 24, 2026, Erasca received a letter from Revolution Medicines, Inc. alleging that ERAS-0015 infringes on Revolution's U.S. Patent No. 12,409,225 and involves misappropriation of trade secrets. Revolution demanded an immediate cessation of ERAS-0015 activities in the U.S. Erasca believes the claims are without merit and intends to defend vigorously, but litigation could result in injunctions or damages.

Investor Verification Checklist

• IP Litigation Status: Verify the current status of the dispute with Revolution Medicines and any potential impact on the ERAS-0015 clinical program or commercialization rights.
• Cash Burn Rate: Confirm the projected cash burn rate excluding the one-time $150M charge to validate the "second half of 2028" runway guidance.
• License Milestones: Review the specific terms of the Joyo and Medshine license agreements for future milestone payment obligations and royalty rates.
• Clinical Data Readouts: Monitor the timing and results of the ERAS-0015 expansion cohorts and the ERAS-4001 Phase 1 data readout expected in late 2026.
• Stock Dilution: Assess the impact of the recent $242.7M equity raise on existing shareholder dilution and the remaining capacity under the $200M ATM program.